-
FEATURE: Medical ethics – our best chance of restoring distorted health systems?
28 April 2023
A tragic story of loss underlines the need for a new ethical framework for how we manage health
News / ANH Covid Zone / Health / Activism
-
FEATURE: How the Nobel Prize Summit sold out on real science
12 June 2023
Despite noble ambitions, the Washington DC Nobel summit looked more like a breeding ground for AI-infused dogma and big corporate backed pseudoscience
News / ANH Covid Zone / Health / Campaigns
-
The plan for WHO supremacy over human health
11 May 2023
Extreme risks posed by the International Health Regulations amendments and the WHO ‘Pandemic Treaty’ – and what we can do about them
News / ANH Covid Zone / Health / Campaigns
-
Rob Verkerk to lead ANH both sides of the Atlantic
13 April 2023
With challenges to natural health and freedom mounting in the USA, the UK and Europe, ANH USA and International teams consolidate, with Verkerk as leader
-
Rob Verkerk PhD & Meleni Aldridge on TNT radio
28 April 2023
ANH founder, Rob Verkerk, along with ANH executive coordinator, Meleni Aldridge stayed up into the wee small hours to join the Sky Dragon Slaying team on TNT Radio
News / ANH Covid Zone / Health / Activism
-
ANH News Beat (week 8/2023)
23 February 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
ANH News Beat (week 12/2023)
23 March 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Natural News Roundup (week 44/2022)
02 November 2022
Vaping can harm your health!; Artificial sweeteners damage kids health; Insects are an essential part of our ecosystem; UK government inflates number of GPs; To eat meat or not?
-
ANH News Beat (week 5/2023)
01 February 2023
A roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Are you up for taking Big Pharma's new 'skinny' jab?
16 March 2023
After a succession of Big Pharma failures for anti-obesity drugs, will Novo Nordisk's latest offering, that emerges from something of a dark cloud, be just another side effect ladened sticking plaster, or a boon for users and a cash cow for its manufacturer?